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The BK channel protein is a multimeric structure (homotetramer) composed of four identical pore-forming α 
subunits (BKα), encoded by a single gene (Slo1, KCNMA1). Each BKα has seven trans-membrane segments 
(S0-S6) and a large intracellular C-terminus region. The BKα protein shows three main structural domains, 
each with a distinct function. The voltage-sensing domain (VSD) is located within the S1-S4 trans-
membrane segments, able to sense membrane potential. The S5-S6 segments form the pore gate domain 
(PGD) including the activation gate, which controls K+ flux through the channel. The S6 segment serves as 
the major structural determinant for the channel gate. The primary voltage sensor is located on the S4 
helix, which contains many positively charged residues, but only one of these participates in voltage 
sensing. The membrane-spanning domains VSD and PGD, interact through the S4-S5 linker and S6, and the 
hydrophobic segment (S0) leads to an extracellular NH2 terminus. The third domain is the cytosolic domain 
(CTD), which enables the channel to respond to changes in [Ca2+]i and other stimuli. The intracellular C-
terminus has two tandem RCK (regulator of K+ conductance) domains, RCK1 and RCK2, folded tightly 
against each other.  Channel sensitivity to Ca2+ is determined by a gating ring of eight RCK domains from 
the four assembled α subunits; this gating ring is subjected to an expansion during channel gating. RCK2 
domains have an aspartate-rich region that forms the ‘Ca2+ bowl’, showing a high Ca2+ affinity. A low-
affinity Ca2+ recognition site has also been identified within the RCK1 domain, where another high-affinity 
Ca2+site is also present. RCK1 also mediates the channel’s sensitivity to Mg2+, Zn2+and Cd2+. The four β-
subunits (β1-4) are encoded by a specific gene KCNMB1-4 (human) or kcnmb 1-4 (mouse). These BK 
channel subunits have two transmembrane domains (TM1 and TM2) connected by a large loop on the 
extracellular side. β-subunits also show an intracellular N-terminus and C-terminus. Each β-subunit is 
located between two adjacent α-subunits. γ subunits contain a single transmembrane domain, an N-terminal 
extracellular LRRD (leucine-rich repeat domain), and a short C-terminal tail.  
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Are BK (big potassium)-type Ca
2+
-activated potassium channels a viable target for the 
treatment of epilepsy? 
 
Abstract 
Introduction: BK (big potassium) channels are Ca
2+
-activated K
+
 channels widely expressed 
in mammalian cells. They are extensively distributed in the CNS, the most abundant level 
being found in brain areas largely involved in epilepsy, namely cortex, hippocampus, 
piriform cortex, and other limbic structures. BK channels control action potential 
shape/duration, thereby regulating membrane excitability and Ca
2+
 signalling.  
Areas Covered: The potassium channel superfamily represents a rich source of potential 
targets for therapeutic intervention in epilepsy. Some studies have identified alterations in 
BK channel function, therefore, supporting the development of drugs acting on these 
channels for epilepsy treatment.  
Expert Opinion: The actual sketch is intriguing and controversial, since mechanisms altering 
the physiological role of BK channels leading to either a loss- or gain-of-function have both 
been linked to seizure onset. Not many studies have been performed to unravel the efficacy 
of drugs acting on these channels as potential antiepileptics; however, paradoxically, efficacy 
has been demonstrated for both BK channel openers and blockers. Furthermore, their 
potential usefulness in preventing epileptogenesis has not been investigated at all. Substantial 
data on risks and benefits of modulating these channels are urgently needed to draw a 
definitive conclusion on whether BK channels are a viable future target for the treatment of 
epilepsy.   
 
Keywords: BK potassium channels; Epilepsy; Seizures; BK channel modulators; 
Antiepileptic drug (AED). 
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List of abbreviations 
[Ca
2+
] = Calcium concentration 
[Ca2+]i = Intracellular calcium concentration 
AEA = N-arach-idonylethanolamine 
AED = Antiepileptic drug 
AHP = afterhyperpolarizationAfterhyperpolarization 
Aps APs = Action potentials 
4-AP = 4-Aminopyridine 
ASN = Asparagine 
Asp = Aspartate 
ATP = Adenosine tri-phosphate 
BK, BKCa, MaxiK, Slo1, KCa1.1, KCNMA1 = Big potassium channel or Big conductance 
calcium-activated potassium channel 
BKα = α subunit of BK channel 
C-linker = Carboxy linker 
C-terminus = Carboxy terminus 
CA = Carbonic anhydrase 
CA1 = Cornus ammonis 
Ca2+ = Calcium ions 
Cav  = Calcium channel 
cAMP = Cyclic adenosine monophosphate 
CB = Cannabinoid receptors 
CBD = Ccannabidiol 
CBDV = Cannabidivarin 
Cd2+ = Cadmium ions 
cGMP = cyclicCyclic-guanosine monophosphate 
CNS = Central nervous system 
Highlights Box 
 
• BK channels control action potential shape and duration, thereby  regulating 
membrane excitability and Ca
2+
 signalling; 
 
• Mechanisms altering the physiological role of BK channels leading to either a 
loss- or gain-of-function have both been linked to seizure onset; 
 
• Efficacy has been demonstrated for both channel openers and blockers in 
preventing seizures; 
 
• BK channels might also be involved in epileptogenesis, however, no studies on the 
efficacy of BK channel modulators in preventing epileptogenesis have been 
performed so far; 
 
• The molecular structure of BK channels is described and allows the possibility of 
several target sites for potential pharmacological modulation. 
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COX-2 = Cyclooxygenase-2 
cryo-EM = cryo-Electron Microscopy 
CTD = Cytosolic domain 
DHA = docosahexaenoic Docosahexaenoic acid 
dSlow = drosophila Drosophila Slowpoke 
ER = Endoplasmic reticulum 
fAHP = fast afterhyperpolarization 
GABA = γ-Aminobutyric acid 
GH3 = Rat pituitary cells 
Glu = Glutamate 
GMP = Guanosine monophosphate 
H+= Hydrogen ions 
hSlow = human Slowpoke 
IK = Intermediate potassium channel or Intermediate conductance calcium-activated 
potassium channel 
IP3 = Inositol tri-phosphate 
K
+
= Potassium ions 
KCa = Calcium-activated potassium channel 
Kv or KCNQ = Potassium channel 
LRRCs = Leucine-rich repeat-containing subunits 
mAHP = medium afterhyperpolarization 
MAPK = Mitogen-activated protein kinase 
MES = Electroshock-induce seizures 
Mg
2+
 = Magnesium ions 
mitoBK = mitochondria Big Potassium channel 
ms = millisecond 
mSlow = mice Slowpoke 
Na
+
 = Sodium ions 
Nav = Sodium channel 
NE =  Nuclear envelope 
NH2 or N terminus = Amino terminus 
NMDA = N-methyl-D-aspartate 
NO = Nitric oxide 
PEA = N-palmitoylethanolamine 
PGD = Pore gate domain 
PI 3-kinase = Phosphoinositide 3-kinase 
PKA = Protein kinase A 
PKC = Protein Kinase C 
PPAR-α = Peroxisome proliferator-activated receptor-alpha 
PTZ = Pentylenetetrazole 
RCK = Regulator of K
+ 
Conductance 
ROS = Reactive oxygen species 
s = second 
S = trans-membrane segment 
sAHP = slow afterhyperpolarization 
SK = Small potassium channel or Small conductance calcium-activated potassium channel 
Slo = Slowpoke 
STREX = Stress axis hormone-regulated exon 
TM = Transmembrane domain 
TRPV = Transient receptor potential vanilloid 
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VSD =  Voltage-sensing domain 
Zn
2+
 = Zinc ions 
ZNS = Zonisamide 
τ = Time constant 
 
 
1.    Introduction 
Calcium-activated potassium channels (KCa) are a large and diversified family of ion 
channels that transduce increases in intracellular Ca
2+
 ([Ca
2+
]i) into changes in membrane 
potential (hyperpolarization) that can then influence the duration and frequency of action 
potentials (APs) in excitable cells (both pre- and postsynaptically) and thus exert an important 
influence on their functional properties. According to their single channel conductance, Ca2+-
activated K
+
 channels can be divided into three subfamilies: small conductance (SK: 2-25 pS), 
intermediate conductance (IK: 25-100 pS) and large conductance (BK: 100–300 pS) subtypes; 
each subgroup also exhibit distinct pharmacological and biophysical characteristics1-4. In 
addition to their important regulatory roles, Ca
2+
-activated K
+
 channels also have an important 
potential as targets for novel therapeutic drugs in health and disease5-7. The BK channel (also 
referred to as BKCa, MaxiK, Slo1, KCa1.1) was the first of the Ca
2+
-activated K
+
 channels to 
be identified and is one of the most widely expressed channels in mammalian cells and tissues 
such as neurones, skeletal, smooth and cardiac muscles, exocrine cells, and the inner sensory 
hair cells of the cochlea8-10. BK channels are also unique in being activated both in response 
to membrane depolarization and an increase of [Ca
2+
]i intracellular [Ca
2+
] (allosteric 
activation); in contrast, SK and IK channels are voltage-insensitive and are solely activated by 
increases in [Ca
2+
]i. Voltage and Ca
2+
 gating sites are separately coupled to the channel 
protein and trigger several conformational changes to activate the BK channel9. Even though 
experimentally, membrane voltage and fluctuations in [Ca
2+
]i by themselves are able to alter 
BK open channel probability, many observations have demonstrated that both membrane 
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depolarization and micromolar rises in  [Ca2+]i are specifically required to open BK channels 
under physiological conditions. Accordingly, BK channels, depending on their location, 
connect changes in [Ca
2+
]i  to outward hyperpolarizing K
+
 currents that can affect postsynaptic 
cell firing as well as presynaptic neurotransmitter release7, 11. Moreover, intracellular Mg2+ 
and
 
H
+ 
ions are also able to
 
regulate BK channels; specifically, millimolar intracellular Mg
2+ 
(binding to a site distinct from the Ca2+ binding site), can activate the BK channel12, and 
decreasing or increasing intracellular pH (acting via the RCK1 sensor), enhances or reduces 
BK channel opening, respectively13. This sensitivity of BK channels to intracellular H+ ions 
could be an important mechanism contributing to termination of epileptic seizure events, 
known to be associated with intracellular neuronal acidification14. BK channel functions can 
also be regulated by ubiquitination and palmitoylation, which seem to control the cell surface 
expression and activity of BK channel proteins. Indeed, myristoylation seems to allow 
endocytosis15-17. Additionally, other endogenous mediators such as arachidonic acid, NO, 
zinc, GMP, cGMP and cAMP-mediated phosphorylation of the channel may regulate BK 
channel activity13.  
In neurones, the activation of BK channels results in an increased efflux of K
+ 
from the cell 
(outward current); as a consequence, the membrane potential is driven in a negative direction 
(decreased cell excitability) and voltage-dependent Na
+ 
and Ca
2+ 
channels are closed, so the 
probability that an AP is triggered is decreased. Therefore, these channels function as 
“negative feedback regulators” of membrane potential and [Ca
2+
]i and play crucial roles in 
several physiological functions, such as controlling the inter-spike interval and spike 
frequency adaptation, neurotransmitter release, endocrine secretion, tuning hair cell tuning 
frequencies, as well as urinary bladder and respiratory neurone network ‘tone’.  
More recently, it has been recognised that BK channels can associate with a variety of G 
protein-coupled membrane receptors (mainly on peripheral smooth muscle, but also in the 
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brain) including muscarinic acetylcholine receptors, β-adrenergic receptors, thromboxane A2 
receptors and angiotensin II receptors, indicating a potential involvement in a wide variety of 
physiological functions in addition to regulation of cell excitability. Furthermore, they appear 
to complex with a variety of cytosolic proteins controlling cellular function, proteins of the 
endoplasmic reticulum, nucleus and mitochondria as well as kinases involved in cell 
death/survival, further raising their importance in maintaining normal physiological metabolic 
processes. It is not too surprising therefore, that identified BK channel malfunction is 
increasingly being linked with important human brain, metabolic and cardiovascular diseases 
including obesity and cancer and that much interest is now being shown in BK channels as 
potential therapeutic targets18. Dysfunction of BK channels has been implicated in the onset 
of certain epilepsies, motor deficits, hypertension, asthma, abnormal circadian rhythms, 
defects in immunity and other disorders19-22. Defective BK channels are also thought to 
contribute to the physiopathology of neurological disorders such as schizophrenia23, autism 
and mental retardation
24
.  
Epilepsy involves alterations of normal physiological processes in the brain. An epileptic 
seizure is produced by synchronous and sustained firing of a population of neurones. Both 
excitatory and inhibitory influences may be altered, creating a predisposition towards 
excessive synchrony within neuronal populations
25
. About 50 million people in the world now 
have epilepsy, and it is estimated that 40–70 new cases per 100,000 individuals in the general 
population will acquire the disease every year in developed countries, with the risk being 
twice as high in developing countries26. Although approximately 70-80% of humans with 
new-onset epilepsy eventually enter sustained seizure remission during treatment, important, 
unmet needs exist in the drug treatment of epilepsy, including the development of more 
effective and safer AEDs
27, 28
.  
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The aim of this review is to examine current knowledge on the molecular properties, 
pharmacology and genetics of BK channels with a particular attention to their possible 
relevance in the pathophysiology of epilepsy and the likelihood of developing new drugs that 
target BK channels as novel antiepileptics. 
 
2. Molecular structure of BK channels  
Structurally, BK channels share some similarity with the voltage and ligand-gated K+ channel 
superfamily (Figure 1). BK channel proteins are multimeric structures (homotetramers) 
composed of four identical pore-forming α subunits (BKα) each comprising of seven trans-
membrane segments (S0-S6) and a large intracellular C-terminus region
19
.  BKα can be co-
assembled with four different auxiliary modulatory β-subunits (β1-β4), as well as a family of 
leucine-rich repeat-containing subunits (LRRCs) also called γ-subunits.  Each type of β- and 
γ-subunit displays a distinct tissue-specific expression pattern and differently affects the 
conductance properties, inactivation, gating kinetics and pharmacology of the assembled 
channel
29-31
. β2-4 subunits are neuronally expressed, whereas β1 subunits are mainly 
distributed in smooth muscle cells9. BKα is encoded by a single gene (Slo1, KCNMA1), with 
27 constitutive exons and multiple alternative exons spanning. The BK gene was first 
discovered in Drosophila as the slowpoke mutation (dSlo) and later was identified also in 
mice (mSlo1) and humans (hSlo1).  In mammals, the constitutive exons of the BKα gene code 
for proteins with ~98% amino acid sequence homology. Each of these constitutive exons is 
designed for a specific function, like the conduction pore, voltage sensor, ‘Ca
2+ 
bowl’ and S0 
trans-membrane segments32.  
Recently, cryo-electron microscopy (cryo-EM) and X-ray crystallography studies of the BKα 
protein have revealed three main structural domains with distinct function and the assembly 
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and interactions among these domains33, 34. These interactions are critical for activation of the 
channel in response to physiological changes of membrane potential, and intracellular levels 
of Ca
2+
 and Mg
2+
. Briefly, the voltage-sensing domain (VSD) characteristically located within 
the trans-membrane segments S1-S4 is able to sense membrane potential, whereas the 
segments S5-S6 form the pore gate domain (PGD) and within its resides, the activation gate, 
which controls the K+ flux through the channel32, 35, 36.  Moreover, S6 is believed to serve as 
the major structural determinant for the channel gate. The primary voltage sensor is located 
on the S4 helix, which contains many positively charged residues (basic residues) but only 
one of these, has been shown to participate in voltage sensing
37
. VSD and PGD, also called 
the membrane-spanning domains, can interact through the S4-S5 linker and S637. 
Furthermore, BK channels have a hydrophobic segment (S0) that leads to an extracellular 
NH2 terminus and additional four intracellular hydrophobic segments (S7-S10) in the C-
terminus. The first transmembrane segment, S0, is required for β-subunit modulation and can 
participate to modulate voltage sensitivity. The third domain is the cytosolic domain (CTD), 
which confers on the BK channels the ability to respond to changes in [Ca2+]i and other 
stimuli.  
The crystal structure of the BK channel in the intracellular C-terminus has defined two 
tandem RCK (regulator of K
+ 
conductance) domains, RCK1 and RCK2
36
. These tandem 
domains are folded tightly against each other and channel sensitivity to Ca2+ is determined by 
a gating ring of eight RCK domains from four assembled α subunits. The gating ring formed 
by RCK1 and RCK2 is subjected to an expansion during the channel gating. RCK2 domains 
have an aspartate-rich region that forms the ‘Ca
2+
 bowl’, which is located in the distal region 
of the C-terminus (S9-S10) and confers a high Ca2+ affinity. The low-affinity Ca2+ recognition 
site has been identified within the RCK1 domain, where another high-affinity Ca
2+
site is also 
present. RCK1 also mediates the channel’s sensitivity to Mg2+, Zn2+and Cd2+. Most likely, 
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Mg2+ binds to a site in between VSD (Asp99 and ASN172) and RCK1 (Glu 374 and Glu 399), 
allowing it to influence the VSD with an electrostatic interaction, and as a consequence, the 
BK channel can be opened. Hence, it has been established that the interaction between VSD 
and CTD may occur during channel gating36, 38-40. Likewise, PGD and CTD can connect 
through the C-linker peptide and its length affects the activity of BK channel. Moreover, other 
residues located in the C-terminus allow the linking with molecules, such as heme and carbon 
monoxide, which modulate the gating properties of the BK channels
41
. The cytosolic region 
also includes phosphorylation sites for protein kinase A (PKA) and protein kinase C (PKC). 
Generally, PKA phosphorylation leads to BK channel enhancement, whereas PKC 
phosphorylation leads to channel inhibition.  
The four β-subunits (β1-4) are encoded by a specific gene KCNMB1-4 (human) or kcnmb1-4 
(mouse). These BK channel subunits have two transmembrane domains (STM1 and STM2) 
connected by a large loop on the extracellular side. Moreover, β-subunits show an 
intracellular N-terminus and C-terminus. Each β-subunit is located between two adjacent α-
subunits and alters the pharmacological sensitivity of BK channels, as well as their regulation 
by phosphorylation, which involve multiple distinct mechanisms. For example, BKβ subunits 
1, 2 and 4 seem to stabilize the BK VSD in the active conformation, whereas BKβ 2 and 3 
subunits confer BK channel inactivation via an N-terminal inactivation ball, and related minor 
K+ efflux31, 42, 43.  In most tissues, the BKα subunit can be linked with up to three β-subunits42. 
So far, it has not been possible to elucidate how the interdomain interactions among the three 
main domains VSD, CTD, and PGD are modified by β-subunits to influence channel 
activation
7, 9
. The ability of γ-subunits to bind and to modify BK channel kinetics and gating 
behaviour still remains unclear. However, it seems that all γ-subunits enhance voltage-
dependent activation of BK channels
30, 31
. 
[Figure 1 near here] 
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3. BK channels in the central nervous system: distribution and pharmacological 
properties 
BK channels are widely distributed both in the central nervous system (CNS) and peripheral 
nervous system, with consistent expression both in the cell body and at the presynaptic 
terminal. BK channels are closely co-localized near the Ca2+ sources, such as voltage- 
dependent Ca
2+
channels, ryanodine receptors, IP3 receptors and N-methyl-D-aspartate 
(NMDA)-type glutamate receptors. The voltage-gated calcium channel (Cav) subtypes that 
interact with BK channels differ from neurone to neurone and comprise of Cav1.2 (L-type), 
Cav2.1 (P/Q-type), Cav2.2 (N-type) and Cav3 (T-type)
44. Abundant levels of α-subunits in the 
CNS have been identified in the cortex, hippocampus, olfactory system, piriform cortex, and 
other limbic structures. Both in cortex and hippocampus, α-subunits are mostly expressed in 
glutamatergic synapses, whereas in the cerebellum, they are expressed at GABAergic nerve 
terminals
3, 44-46
.  In CNS areas, such as cortex, hippocampus and cerebellum, α-subunits have 
also been detected in the inner mitochondrial membrane (mitoBK). Similarly to BK, mitoBK 
is selectively permeable to K
+ 
and is activated by both voltage and [Ca
2+
]i. It seems that there 
are, at least, two type of mitoBK in the brain, but so far, their structure remains unknown47. 
 
The β-and γ-modulatory subunits have a limited expression pattern in the brain. The β4- 
subunit is the most expressed neuronal subunit. This subunit, in a Ca
2+
 concentration- 
dependent manner, produces mixed effects on BK channel gating. In particular, in the 
presence of a low local Ca
2+
 concentration, the β4-subunit decreases the activation of BK 
channels, whereas at high Ca2+ concentration, the BK channel activation is increased. The 
other subunits expressed in the brain are β2 and β3, whereas smooth muscle cells primarily 
express the β1 subunit29, 48.  
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Electrophysiological and pharmacological evidence suggests that α-subunit interactions with 
β2- and β4-subunits determine the BK channel subtypes observed in the CNS. Essentially, 
three central neuronal BK channel subtypes can be identified: 1) type I showing rapid 
activation and N-type “ball-and-chain” inactivation (α + β2)
49
; 2) or the non-inactivating type 
I (α alone) and 3) type II (α + β4).  Paxilline (an indole diterpene alkaloid derived from 
Penicillium paxilli), has been identified as a useful, selective and reversible blocker of type I 
and type II BK channels50. The β2-subunit is able to confer N-type inactivation to BK 
channels, which are sensitive to block by iberiotoxin (from the red scorpion Buthus tamulus) 
and charybdotoxin (from the scorpion Leiurus quinquestriatus). In the CNS, these types of 
BK channel are mainly localized in the hippocampus; and they seem to be responsible for the 
early repolarization after a short burst train of APs in a train. Interestingly, the β4-subunit 
renders type II BK channels refractory to iberiotoxin and charybdotoxin block, but they are 
selectively inhibited by martentoxin, a peptide purified from the venom of the East-Asian 
scorpion Buthus martensi51. Moreover, type II BK channels are less sensitive to [Ca2+]i  and 
have slow gating kinetics.  
 
Type I BK channels have relatively fast gating kinetics and are sensitive to scorpion venom 
block35, 43, 46. The study of the role of these channels in the CNS has been facilitated by 
iberiotoxin and other inhibitors, such as paxilline, lolitrem B (from the ryegrass fungus 
Acremonium lolii) and penitrem A (from Penicillium cyclopium)52. The principal role of BK 
channels is to generate the fast neuronal afterhyperpolarization (fAHP) seen immediately after 
an AP. AP repolarization and the fAHP participate significantly to affect AP shape and 
duration. Generally, BK channels are relatively slowly activated during an AP; the fast AP 
upstroke and consequent Ca2+ influx also activates other Ca2+-dependent conductances such 
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as SK channels, to contribute towards inhibition of repetitive firing. Thus, BK channels 
through the control of AP shape and duration have an important function in regulating 
membrane excitability and Ca
2+
 signalling
10, 53
.  
 
The AHP, following single or longer bursts of APs, is composed of multiple kinetic 
components that have been well characterized in the hippocampus54. In hippocampal CA1 
neurones, it was possible to discern three potassium conductances; the fast component 
(fAHP), that decays with a time constant (τdecay) of ~50 ms, is mediated by BK channels or M-
type K
+
 channels. The two longer-lasting components are both mediated by voltage-
independent, Ca2+-activated K+ conductances; the intermediate (medium) AHP (mAHP), 
which has a decay time constant (τdecay) of ~250 ms, activates during the AP-mediated Ca
2+
 
influx, is mediated by SK channels and is blocked by the bee venom toxin, apamin55. By 
contrast, the slow AHP (sAHP) evoked after a longer (~1s) burst of APs, shows a prominent 
activation phase (τrise ~ 600 ms), and decays slowly, persisting for as long as several seconds. 
In particular, during an AP, membrane depolarization and the increment of cytosolic Ca2+ 
activate BK channels with a reduction of AP frequency. During a fAHP, the membrane 
potential is more negative than the normal resting potential, and returns to baseline slowly. In 
fact, the loss of BK current in a neurone is linked with reduction of the AHP, resulting in a 
higher AP frequency and enhancement of membrane excitability. This delay of the membrane 
potential to reach the normal resting potential after depolarization, results in increased 
interspike intervals and ultimately in control of neuronal excitability53, 56, 57. Following a 
fAHP, many neurones show a prolonged AHP that is generated by SK channels. This 
prolonged AHP also plays an important role in controlling spike frequency57.  
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BK channels are also involved in the regulation of CNS neurotransmitter release4. This 
activity is correlated with their location around Cavs. It seems that at presynaptic terminals, in 
response to a prolonged depolarization and Ca
2+
-influx, BK channels limit the number of APs 
and the subsequent influx of Ca2+, thereby decreasing vesicle fusion and therefore, 
neurotransmitter release. These channels are also capable of enhancing the activity of the 
Na
+
/Ca
2+ 
exchanger to prevent excessive [Ca
2+
]i. During massive activation of neurones, i.e. 
during ischaemia or seizures, BK channels may act as an “emergency” protective system to 
counteract excitotoxic damage46, 58. 
 
Generally, BK channels in the hippocampal CA1 pyramidal cell layer reduce the frequency 
and duration of APs. However, in the past, experiments in rat CA1 pyramidal cells have 
remarked on the ability of BK channels to enhance early high-frequency firing. The reason 
for this facilitation seems to be related to the rapid spike repolarization and fAHP, which can 
restrict the activation of other slower potassium currents and inactivation of the fast AP Na+ 
current
46, 53
. Interestingly, blocking the BK-mediated fAHP with paxilline resulted in an 
impairment of hippocampus-dependent learning during trace eyeblink conditioning in rats59.  
BK channels have also been localized in the inner mitochondrial membrane, but their exact 
role in these organelles
 
is unclear. They are, however, known to be important for Ca
2+
 ion 
sequestration and for K+ transport. The opening of mitoBK channels actually produces a loss 
(depolarization) of the inner mitochondrial membrane potential, which may have a protective 
function, fundamental for the regulation of mitochondrial metabolism60. Indeed, some 
findings indicate neuroprotective properties for mitoBK in specific brain structures
8, 61
. 
Pharmacologically, mitoBK channels are unusual, in that they are blocked by iberiotoxin but 
not by charybdotoxin
62
. It has also been suggested that BK channels are present on the 
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nuclear envelope (NE) of rodent hippocampal neurones, where they may regulate gene 
expression via the control of nuclear Ca2+ signalling63. 
 
4.     BK channels and epilepsy pathophysiology 
Under physiological conditions, through a negative feedback mechanism, BK channels 
modulate both neuronal membrane potential and intracellular Ca2+ signalling, actions that 
should in principle, attenuate epileptic seizure bursts. In fact, BK channels, by linking 
changes in intracellular Ca2+ to a fast hyperpolarizing response, would be expected to 
decrease or prevent neuronal hyperexcitability that would lead to seizures. Thus, mechanisms 
altering the physiological role of these channels, such as gene mutations, down or up-
regulation of channel expression, or defects in channel trafficking and insertion into the 
plasma membrane could contribute to the onset of seizures, as well as other neurological 
diseases. In particular, studies have indicated a seizure-related down-regulation of BK 
channels in the hippocampus of chronically epileptic rats. Moreover, seizure-mediated BK 
down-regulation of BK channels principally localized at glutamatergic terminals, could also 
affect neuronal excitability by influencing presynaptic control of glutamate release, with a 
consequent facilitation of seizure events. Thus, it seems that altered BK channel expression is 
a plastic modification mechanism that can affect the network excitability in these epileptic 
animals64, 65.  
 
Both gain- and loss-of-function mutation of genes encoding for the BK channel subunits have 
also been correlated to channelopathies leading to epilepsy disorders. Because the normal 
function of BK channels generally reduces neuronal excitability, loss-of-function mutations 
related to these channels gives rise to neuronal hyperexcitability, which can lead to seizures.  
A single base pair deletion in exon 4 (delA750) of the gene encoding for the β3 regulatory 
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subunit (KCNMB3) has been linked with human idiopathic generalized epilepsy (particularly 
absence epilepsy), most likely through reduced levels of inhibition66, 67. On the other hand, a 
study has also highlighted the presence of a gain-of-function gene mutation in the α-subunit 
(KCNMA1) on chromosome 10q22 in the pathogenesis of a human syndrome characterized by 
generalized epilepsy and paroxysmal dyskinesia. The mutation led to an increase in BK open-
channel probability, which the authors proposed led to an increased excitability in vivo by 
inducing rapid repolarization of APs, thereby permitting neurones to fire at a faster rate
20
. 
Likewise, a gain-of-function in a mouse knockout of the inhibitory β4-subunit has also been 
linked to epilepsy, most likely through a similar ‘sharpening’ effect on APs
68
. 
 
In animal models of epilepsy, the loss-of-function mutation has been involved in the 
development of seizures and related neurological disorders. Intracellular recordings in rat 
subicular neurones revealed a transient depression of the fast and slow AHP during the course 
of kindling that may contribute to the induction but not permanence of the kindled state
69
. 
Moreover, other data associated the loss-of-function mutation with the development of 
epileptogenesis. In particular, epileptogenesis in mesial temporal lobe epilepsy seems to be 
determined by several factors including abnormalities in the expression and function of ion 
channels, such as the BK channel
65
. Liu et al.
70
 demonstrated that BK channels are targeted by 
the E3 ubiquitin ligase CRL4ACRBN for polyubiquitination and are therefore withheld in the 
endoplasmic reticulum (ER) and inhibited from trafficking to the cell membrane. 
Deregulation of this physiologic mechanism gives rise to a release of deubiquitinated BK 
channels from the ER to the plasma membrane, leading to significantly increased channel 
activity. Mice with the CRL4ACRBN mutation in the brain or treated with a CRL4ACRBN 
inhibitor are very susceptible to seizure induction, which can be reduced by blocking BK 
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channels (see below). Because the CRBN gene is widely expressed in the hippocampus, it 
plays a fundamental role in the development of limbic seizures70. 
 
It has been demonstrated that the BK channel β4-subunit reduces dentate gyrus excitability 
and protects against temporal lobe seizures, thus β4 knockout mice present temporal lobe 
seizures emerging from the dentate gyrus56. Likewise, gain-of-function mutations, facilitating 
high-frequency neuronal firing, are (paradoxically) associated with spontaneous seizures in 
both rodents and humans. In fact, patients with generalized epilepsy (particularly absence 
epilepsy) and dyskinesia showed a point mutation in the RCK1 domain of the α-subunit (i.e., 
D434G). This mutation increased the neuronal BK channel opening time, through 
enhancement of the voltage and Ca
2+
 sensitivity of the channel. Functionally, an increased 
activity of the BK channel and the consequent fAHP are associated with an enhanced 
membrane excitability. This augment seems to be caused by an enhanced recovery rate of the 
fast Na
+ 
current with a reduced refractory period of neuronal APs and/or through a 
disinhibition of thalamocortical circuits by blocking GABAergic interneurones20, 53, 68. It has 
been demonstrated that the presence of β1, β2, and β4-subunits of BK channels enhances the 
D434G mutation. It was also reported that polymorphism in the β4-subunit is associated with 
human epilepsy
71
. 
 
The mitochondrial mitoBK
 
has also been associated with various disorders including 
epilepsy; however, the mechanism by which functional deficits in mitoBK take part in 
epileptogenesis is unclear. Nevertheless, the possible role of these channels in suppressing 
seizures could be due both to a reduction of the production of reactive oxygen species (ROS) 
and to reduction of the accumulation of deleterious intra-mitochondrial Ca
2+72
.  
 
Page 17 of 48
URL: http://mc.manuscriptcentral.com/eott  Email: Claudia.Palmer@informa.com
Expert Opinion On Therapeutic Targets
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 17
According to the above studies, the role of BK channels in various epileptogenic phenotypes 
can be highlighted. Usually, the activation of these types of channel leads to a reduced 
excitability. Therefore, it would be easy to propose that epilepsy might be treated with drugs 
that enhance the activation of BK channels, akin to the recent introduction of retigabine, a 
known M-type K
+
 channel activator, in epilepsy management
73
. However, the actual 
realization may be far more controversial. Indeed, as mentioned above, epileptic phenotypes 
have also been associated with an increased activity of these channels (i.e. gain-of-function 
mutations). Moreover, the prediction of the outcome of these channel mutations is very 
complicated. Alternative splicing of BKα KCNMA1 contributes to different complex 
phenotypes and various functional changes, including altered sensitivity to Ca2+ and/or 
voltage, responses to phosphorylation, signalling cascades, membrane expression regulation, 
trafficking and lipidation74. The functional heterogeneity that can appear after alternative 
splicing, polymorphisms, phosphorylation and protein interactions concerns the cytosolic 
domain. Some of these different phenotypes have been linked with epilepsy
74, 75
. The 
phenotype of mutated BK channels varies not only among different tissues or cells, but also in 
the same tissue and cell type under different hormonal environments. The KCNMA1 gene has 
several alternative splice sites and alternative exons
76
. Two of these well-characterized splice 
isoforms, identified in the CNS, are the so-called stress axis hormone-regulated exon 
(STREX) and the ZERO variant. The STREX splice variant in comparison to the ZERO 
variant (that does not contain the STREX domain) contains a 58 amino acid cysteine-rich 
insert at the C2 splice site within the intracellular C-terminus RCK1-RCK2 linker of 
mammalian BK channels that confers increased Ca
2+
 sensitivity to the channel, thus changes 
the kinetics of the channel, and also alters some effects relating to channel phosphorylation by 
PKA
7
. In addition, it has been demonstrated that, gonadal (sex) and adrenal (stress) steroids 
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participate in the regulation of the STREX splicing. Some studies have focused on the 
possible role of STREX expression for the pathogenesis of epilepsy39, 77.  
 
5.    BK channel modulators as potential antiepileptics 
The potassium channel superfamily represents a rich source of potential targets for therapeutic 
intervention. In view of the likely role of BK channels in the aetiology of epilepsy and other 
neurological disorders
24
, a major goal would be to discover selective activators, modulators 
and blockers of these channels, which could be useful in epilepsy therapy and perhaps also for 
treating many other central and peripheral vascular diseases
78
. The activity of BK channels is 
known to be modulated by many endogenous factors, such as acidification, phosphorylation, 
NO, Zn
2+
, ROS, methionine oxidation, cholesterol, arachidonic acid, unsaturated free fatty 
acids such as the omega-3 docosahexaenoic acid and hormones (17β-estradiol and other sex 
and stress steroids). Therefore, drugs that affect the generation of these factors would be 
expected to also modify BK channel activity. In agreement with this notion, some known 
endogenous modulators have been used as a basis for the development of novel compounds 
with BK channel modulatory activity. Notably, some of these compounds regulate BK 
channel function in an β-subunit dependent manner79, 80. However, also natural and synthetic 
compounds may modulate BK channel activation. Among natural compounds, terpenes, 
phenols and flavonoids are able to stimulate BK channels81, but also represent an interesting 
group of compounds that could be used as a suitable scaffold to discover novel BK 
activators52.   
[Table 1 near here] 
 
5.1    BK channel openers/activators in epilepsy 
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Studies have reported the effects of the anorexogenic hormone leptin and insulin to reduce 
epileptiform-like activity in rats and mice hippocampal neurones. Leptin inhibits hippocampal 
neurones by activation of BK channels and K(ATP) channels, a process that can be important 
in regulating neuronal excitability. It seems that the process leading to activation of BK 
channels involves stimulation of phosphoinositide 3-kinase (PI 3-kinase), but not mitogen-
activated protein kinase (MAPK). Exactly the opposite has been observed for insulin. Indeed, 
insulin inhibits neuronal excitability via a process involving MAPK-driven activation of BK 
and K(ATP) channels. Leptin effects were mimicked by the synthetic BK channel activator 
NS1619 (1,3-dihydro-1-[2-hydroxy-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-2H-
benzimidazol-2-one), and inhibited by the BK channel inhibitors, iberiotoxin and 
charybdotoxin. Therefore, this novel action of these hormones could be an alternative 
therapeutic target in the management of epilepsy. Recently, it was argued that the 
neuroprotective effects of leptin in NMDA-exposed cortical neurones in vitro, were 
dependent on BK channel activation, supporting the potential of targeting these channels in 
neurodegenerative diseases82, 83.  
The BK channel openers, isopimaric acid, chlorzoxazone (and NS1619) have been 
demonstrated to moderate inhibition of epileptiform activity induced by 4-aminopyridine (4-
AP) in cultured rat hippocampal neurones, whereas other BK channels openers such as 
NS309, DCEBIO, and 1-EBIO showed potent antiepileptic anti-epileptiform effects similar to 
conventional antiepileptic drugs (AEDs)
82-84
. The use of NS1619 is however, limited by a 
relatively poor potency. In view of this poor activity, NS1619 was used as scaffold to 
generate the biarylthiourea NS11021, a potent compound useful to study the role of BK 
channels. Unfortunately, to date, there are no reports that link this compound with epilepsy.  
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A variety of small synthetic molecules (NS004, fenamates) and natural product-derived 
compounds (DHS-I, maxikdiol) have also been identified as selective BK channel openers, 
which could have some useful effects 
85
.  Riluzole, a drug approved in the treatment of 
motoneurone disease, has been found to stimulate BK channels in rat pituitary GH3 cells86. 
The efficacy of riluzole against seizures in several animal models was previously reported
87, 
88; however, the contribution of BK channels to the anticonvulsant effects of riluzole certainly 
needs to be further investigated. 
 
It was asserted that oestrogen and xenoestrogens may modulate BK channels, and, for some 
of these steroids, the presence of a β-subunit seems to be pivotal for their action. However, 
the binding site and exact mechanism of action of these compounds are unknown
89, 90
. 
Hormones, such as oestrogens, play an important role in epilepsy 91, 92. Tamoxifen, a selective 
oestrogen-receptor modulator, seems to bind to these channels on the extracellular side. It has 
been shown that tamoxifen enhances the antiseizure efficacy of some AEDs against 
electrically and pentylenetetrazole-induced seizures in mice. These antiepileptic effects of 
tamoxifen could also be the consequence of BK channel modulation
93, 94
. 
 
Zonisamide (ZNS), a second generation antiepileptic drug, has also demonstrated its clinical 
efficacy in treating neuropsychiatric disorders. The precise antiepileptic mechanism of ZNS 
(possessing a sulphonamide side chain) is still unclear. ZNSIt is known to act  possesses 
several mechanisms of action such asthrough the inhibition of voltage-gated Na+ and Ca2+ 
channels and inhibition of carbonic anhydrase (CA)
95, 96
. However, Huang et al, have also 
demonstrated that ZNS increases the activity of BK channels with a related increment in the 
amplitude of K
+
 outward current in hippocampal neurones
97
. ZNS possesses several 
mechanisms of action such as inhibition of voltage-gated Na+ and Ca2+ channels and 
Field Code Changed
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inhibition of carbonic anhydrase (CA)96, 97. These latterCA inhibitors, such as acetazolamide 
(also a sulphonamide), are known to have anticonvulsant activity, and a similar mechanism 
might also contribute to the anticonvulsant effects of topiramate (an O-sulphamate 
derivative)98. It has been demonstrated that acetazolamide, at concentrations higher than those 
required for the inhibition of CA, were able to activate BK channels in skeletal muscle. 
Therefore, the antiepileptic effect of CA inhibitors could also be related the activation of these 
channels in neurones
99, 100
. However, CA inhibitors might also influence BK channel activity 
by altering brain pH. Similarly, COX-2 is known to be rapidly induced during seizures, and 
COX-2 inhibitors have been demonstrated to possess antiepileptic anticonvulsant effects
101, 
102.  Since arachidonic acid is known to activate BK channels, the relevance of COX-2 
inhibition and arachidonic acid metabolism to the anticonvulsant action of such drugs needs 
to be further studied and defined103, 104.  
[Table 2 near here] 
 
In several animal models, it has been demonstrated that the plasmalemma BK channels are 
sensitive to membrane cholesterol, their activity being depressed by a rise in levels and vice 
versa. Considering that AEDs are known to raise total plasma cholesterol levels in patients105, 
106
, it would be of interest to determine whether BK channels play a role. The suggested 
anticonvulsant and antiepileptogenic effects possessed by some statins however may not be 
related to changes in cholesterol metabolism
79, 105, 107-109
. Long-chain omega-3 
polyunsaturated fatty acids, such as docosahexaenoic acid (DHA), found in oily fish are able 
to activate BK channels. Moreover, DHA decreases seizures in animal models of epilepsy in 
addition to having neuroprotective effects110, 111. It has been reported that derivatives of the 
alkaloid eburnamine (derived from the Apocynaceae plant family), such as vinpocetine, are 
able to stimulate BK channels in pituitary GH3 rat cells. Vinpocetine has shown 
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neuroprotective properties that could be useful for the treatment of CNS disorders and might 
be linked to this effect via activation of BK channels112, 113. The only compound activating 
BK channels, which has currently entered clinical trials is the new tetrazolyl-benzamido 
derivative Andolast® (CR 2039: Rottapharm, Monza, Italy)114 which exhibits antiallergic, 
antiinflammatory, mucosal protective and antisecretive activities. It showed good tolerability 
in mild asthmatic patients115 and was previously shown to enhance the anticonvulsive effects 
of some AEDs against seizures induced by pentylenetetrazole (PTZ) and maximal 
electroshock (MES) in mice116, 117.   
 
5.2      BK channel blockers in epilepsy 
Previous studies (described above) have identified the ability of gain-of-function mutations 
giving rise to seizures both in rodent models and humans. Moreover, these studies have also 
reported that seizures themselves lead to up-regulation of BK channel currents with 
consequent elevated network excitability. In particular, this correlation has been observed in 
experimental models of generalized tonic-clonic seizures induced by the GABAA receptor/ion 
channel blocker picrotoxin and other chemoconvulsants. The elevated excitability in 
neocortical neurones induced by picrotoxin leads to generalized epilepsy that can be reduced 
by the BK channel antagonist paxilline. According to this, also other drugs that bind and 
block BK channels might decrease seizures. Studies have shown both the anticonvulsant 
effects of antiarrhythmic drugs, such as verapamil, and the ability of some of these drugs to 
inhibit BK channels. Therefore, it would be interesting to investigate the potential link 
between the effects of antiarrhythmics on BK channels and their anticonvulsant effects
118-123
. 
Likewise, the absence antiepileptic drug ethosuximide, approved for the treatment of absence 
seizures, in addition to its activity on Cav3 (T-type) channels, is also able to inhibit neuronal 
BK channels, thus this mechanism might also contribute to its antiepileptic activity119, 124.  
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6.     BK channels and cannabinoids in epilepsy 
Studies have shown the potential role of phyto- and endocannabinoids as novel therapeutic 
agents in CNS disorders, such as epilepsy and neurodegenerative diseases. However, 
psychotropic effects of these agents limit their therapeutic use
125
. Recently, some 
phytocannabinoids without psychotropic effects were found to improve CNS disorders like 
epilepsy. These nonpsychotropic compounds, such as cannabidivarin (CBDV) and 
cannabidiol (CBD) produce many pharmacological effects that are not mediated by or are 
partly mediated through putative CB1/CB2 cannabinoid receptors. For this reason, various 
studies have been performed to explain the antiepileptic effects of these nonpsychotropic 
compounds, and clarify their potential mechanisms of action. It seems that among their 
potential target effects, two different channels, namely TRPV (transient receptor potential 
vanilloid) and BK, could directly or indirectly be involved126. This point is also supported by 
the central effects of N-palmitoylethanolamine (PEA) against pain and seizures
127-129
. PEA is 
an endogenous fatty acid amide analogue of the endocannabinoid anandamide (N-arach-
idonylethanolamine; AEA) and it is produced on-demand within the neuronal membrane lipid 
bilayer; it has several proposed mechanisms of action including PPAR-α (peroxisome 
proliferator-activated receptor-alpha) activation
130
. Recently, it was proposed that BK 
channels may act as short-term intermediates for PPAR-α anti-nociceptive actions
129, 131
. 
 
A further link between the endocannabinoid system and epilepsy was also recently suggested 
by Shirazi-zand et al. 
132
; it was demonstrated that the intracerebroventricular administration 
of CBD increases seizure threshold for PTZ-induced tonic seizures. The BK channel blocker, 
paxilline did not produce significant changes in seizure threshold when administrated alone. 
However, when paxilline was administrated together with CBD, it was able to decrease the 
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antiepileptic activity of CBD in this model. These latter results suggest that CBD effects on 
BK channels might be relevant for its anticonvulsant action. However, in the same study, both 
these drugs showed anticonvulsant properties against electroshock-induce seizures (MES) in 
mice, while not interfering when administered together. The authors concluded that a link 
between CBD and BK channels relating to antiepileptic efficacy might exist, although this 
relationship might be relevant only in some animal models and therefore epilepsy seizure 
types
132
.   
 
Conclusions 
BK channels are widely distributed in the CNS, both in the cell body and at the presynaptic 
terminal; the most abundant level of BK channels is found in brain areas largely involved in 
epilepsy, namely cortex, hippocampus, piriform cortex, and other limbic structures. This wide 
distribution emphasizes their contribution in the control of CNS excitability. BK channels are 
responsible for the generation of the fAHP seen immediately after an AP. BK channels 
through the control of AP shape and duration, have an important function in regulating 
membrane excitability and Ca
2+
 signalling. Physiologically, an increase in K
+
 conductance 
might correspond to a reduction in cell excitability; however, BK channels seem to have a 
modulatory effect, which might lead to increased excitability when their function is either 
increased or decreased. In agreement, BK channels have been demonstrated to either inhibit 
or enhance firing frequency in rat hippocampal CA1 pyramidal cells. This ability is directly 
connected to the shape of APs. Not surprisingly, BK channels are physiologically highly 
modulated by several endogenous modulators. Finally, the role of such channels in the CNS is 
further complicated by their ability to modulate neurotransmitter release.  
In theory, under physiological conditions, through a negative feedback mechanism, BK 
channels modulate both neuronal membrane potential and intracellular Ca2+ signalling, 
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actions that should attenuate epileptic seizure bursts.  The actual sketch is actually intriguing 
and controversial, since mechanisms altering the physiological role of these channels, such as 
gene mutations, leading to both a loss- or gain-of-function have been linked to seizure onset.  
Usually, the activation of these types of channel leads to a reduced excitability. Therefore, it 
would be easy to propose that epilepsy might be treated with drugs that enhance the activation 
of BK channels. 
Surprisingly, only few studies have addressed the effects of selective BK channel openers in 
epilepsy models and no proconvulsant effects have been reported to date (summarized in 
Table 1). On the other hand, the BK channel blocker paxilline showed consistent 
anticonvulsant effects in various animal models of epilepsy. However, the efficacy of 
paxilline has been observed in models where a gain-of-function was observed. Indeed, 
paxilline has anticonvulsant effects in the MES model where the function of these channels 
might not be altered. Noteworthy, paxilline does not have any effect against PTZ-induced 
seizures while blocking the effects of CBD in the same model. Furthermore, it cannot be 
excluded that the anticonvulsant effects of the available BK channel modulators might be due 
to other off-target mechanisms of action possessed by these drugs, such as inhibition of Ca
2+
 
channels6. 
In conclusion, while BK channels are undoubtedly involved in the regulation of neuronal 
excitability, their role and the effects of their modulation in the potential management of 
epilepsy still remain widely controversial. 
 
Expert Opinion 
The K+ channel superfamily represents a rich source of potential targets for therapeutic 
intervention. As previously mentioned, retigabine is the only selective modulator drug (acting 
on M-type K+) channels currently marketed for the treatment of epilepsy. The validity of K+ 
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channels as a suitable target is further supported by the current development of ICA-105665, 
a novel small molecule opening Kv7.2/7.3 and Kv7.3/7.5 potassium channels, also known as 
KCNQ2/3 and KCNQ3/5 channels. This compound has shown a broad spectrum of activity in 
epilepsy/seizure animal models and epileptic patients133. Finally, several available AEDs are 
also acting on K
+
 channels among their multiple mechanisms of action; e.g. topiramate, 
oxcarbazepine, lamotrigine, carbamazepine, ethosuximide98, 124, 134-137.  
Despite the great number of marketed AEDs, there is still a great need for more effective, 
specific and safer drugs28. In this light, both clinical and preclinical research in this field is 
clearly looking for new directions to be followed in agreement with the strong need to modify 
the current approach which has been followed up to date28.  
Considering BK channels, the results obtained so far, in the understanding of their 
physiological and pathological role in several neurological diseases including epilepsy, 
strongly encourage further studies. It is clear that BK channels have a great influence in the 
regulation of neuronal excitability and alterations in their function can represent both the 
cause and the consequence of seizures and epilepsy. It is easy to believe that BK channels 
must be considered a suitable target for new AED development; however, the current 
knowledge does not allow clear-cut conclusions. 
Substantial data have identified mutations and alterations in the function of BK channels both 
in epileptic patients and epilepsy animal models; therefore, there is no doubt that they are 
involved in the hyperexcitation observed in the epileptic brain. Unfortunately, the physiology 
of this channel allows the possibility that either an impairment or increase in BK function can 
lead to hyperexcitability. This latter point implies a difficulty in predicting their role even if 
an alteration is identified. Namely, if a gain-of-function is found, this might either be the 
cause or a defence mechanism for seizures. To this aim, the only available option is to directly 
test the effects of a BK channel agonist or antagonist; obviously, this is not a feasible clinical 
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approach. Therefore, the first weakness of this research area is the clear need for an 
improvement in the understanding of the function of this channel in pathological conditions. 
Bearing in mind this variability, the therapeutic success of drugs acting on BK channels will 
be highly influenced by predictors of activity in specific syndromes; furthermore, paradoxical 
effects might be expected in some others. This latter consideration rises from the observation 
that both BK channel blockers and openers possess potential anticonvulsant/antiepileptic 
effects. The BK channel blocker paxilline was found to be anticonvulsant in some models 
while blocking the anticonvulsant effects of CBD in another one. BK channels contribute to 
the fAHP and therefore their activation should be considered as a valid tool to decrease 
neuronal excitability; in other words, BK channel blockers should always be pro-convulsant 
or at least reduce seizure threshold. However, there are no reports for paxilline being pro-
convulsant. The complexity brought by modulation of BK channels is reflected by the 
suggestion that over-activation increases AP firing rate and therefore might contribute to 
seizure generation and spreading; these data support the anticonvulsant effects of paxilline 
and/or other BK blockers in some types of seizures where this mechanism is involved. On the 
other hand, the possible anticonvulsant effects of BK openers might instead drive an increase 
in firing rate, precipitating the generation of seizures.  
 
The potential of this research area is likely to be enormous, but assessing the risk/benefit ratio 
of all drugs acting on BK channels will be a great challenge. While several drugs modulating 
BK channels are available, data in epilepsy models are very limited. We believe that a better 
activity profile should be performed in order to understand whether these channels really 
represent a suitable target for AED development. On the other hand, it is very interesting and 
represents a good resource, the observation that several hormones and drugs with 
anticonvulsant activity can act on BK channels among their mechanisms of action; e.g. leptin, 
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insulin, riluzole, zonisamide, acetazolamide, COX-2 inhibitors, DHA and andolast (Table 2). 
All these drugs were found to be openers/activators of BK channels, further supporting the 
idea that an increase in the function of these channels decreases excitability and therefore 
might contribute to the final anticonvulsant effects observed. Therefore, very selective drugs 
should be studied to understand their real value and the role of BK channels in epilepsy, 
whereas, the contribution of BK channel modulation to the anticonvulsant effects of the 
abovementioned drugs might indicate their potential as add-on therapies. 
 
Finally, a very interesting area which has not previously been covered, is the role of BK 
channels in epileptogenesis. BK channels were found to be altered by the epileptogenic 
process in animal models and it remains completely unclear whether this is an adaptive 
response leading to the development of spontaneous seizures, or a defence response. The 
available data support the idea that a loss-of-function is linked to the development of 
spontaneous seizures and therefore, BK channels would underlie the epileptogenic process. In 
this light, it is not surprising that zonisamide (a BK channel activator) has antiepileptogenic 
effects in the WAG/Rij rat absence epilepsy model and that in the same strain, an alteration in 
the function of BK channels has been described 95, 138. 
 
Overall, BK channels are certainly a suitable target for the development of drugs to be used in 
the epilepsy field as well as other neurological disorders. However, the whole area seems to 
hide behind a curtain and the entire portrait appears to be far from being finished. 
Nevertheless, the high degree of potential modulation of these channels (natural and drug-
induced) might offer a new approach for their future pharmacological targeting, further than 
indicating that BK channels have a pivotal role in several CNS functions.  
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Table 1. Anti-epileptiform/anticonvulsant effects of drugs acting on BK channels 
Drugs  
 
Effect on 
BK 
Channels 
Experimental 
model 
Effects Ref. 
Andolast Activator 
Pentylenetetrazole 
model 
Enhances the anticonvulsive 
activity of some antiepileptic 
drugs. 
116
 
Charybdotoxin 
(aggravates 
seizures) 
Inhibitor 
Cultured rat 
hippocampal 
neurones 
Increases neurone 
excitability 
82, 83
 
Chlorzoxazone Activator 
4-Aminopyridine in 
cultured rat 
hippocampal 
neurones 
Inhibits epileptiform activity 
induced by 4-Aminopyridine 
85
 
Iberiotoxin 
(aggravates 
seizures) 
Inhibitor 
Cultured rat 
hippocampal 
neurones 
Increases neurone 
excitability 
82, 83 
Insulin Activator 
Cultured rat 
hippocampal 
neurones 
Inhibits neuronal excitability 
via a process involving 
MAPK-driven activation of 
BK and K(ATP) channels 
82
 
Isopimaric acid  Activator 
4-Aminopyridine in 
cultured rat 
hippocampal 
neurones 
Inhibits epileptiform activity 
induced by 4-Aminopyridine 
85 
Leptin Activator 
Cultured rat 
hippocampal 
neurones 
Regulateshippocampal 
neurone excitability  
83 
NS1619 Activator 
4-Aminopyridine in 
cultured rat 
hippocampal 
neurones 
Inhibits epileptiform activity 
induced by 4-Aminopyridine 
81-85
 
Paxilline (where 
gain-of-function 
was observed) 
Inhibitor 
Chemoconvulsant 
models 
Reduces seizure duration and 
severity 
118, 
119, 
121, 
132
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Table 2. Drugs with known anticonvulsant activity, which may also act on BK channels 
Ligands Evidence References 
Acetazolamide  
• Anticonvulsant activity 
• At high concentrations, binds to BK channels 
in skeletal muscle 
99, 100
 
Cannabidiol (CBD) 
Link between cannabis, epilepsy and BK channels 
might exist 
126, 127, 130, 
132
 
COX-2 inhibitors 
• Antiepileptic effects 
• Arachidonic acid is known to activate BK 
channels 
52, 103, 104 
Docosahexaenoic 
Acid (DHA) 
• Activates BK channels 
• DHA decreases seizures 
52, 80, 110, 111 
Ethosuximide 
• Approved AED 
• Inhibits neuronal BK channels 
124 
Riluzole 
• Stimulates BK channels in rat pituitary GH3 
cells 
• The efficacy of riluzole against seizures in 
several animal models was previously reported 
87, 88
 
Statins 
• Anticonvulsant and antiepileptogenic effects 
• BK channel activity is sensitive to membrane 
cholesterol 
52, 79, 107, 108
 
Tamoxifen 
• Enhances antiseizure activity of some AEDs 
• Binds to BK channels 
90, 93, 139 
Vinpocetine 
• Stimulates BK channels 
• Exerts neuroprotective properties 
112, 113 
Zonisamide 
• Approved AED 
• Increases the activity of BK channels 
 
95, 97 
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 Figure legend 
Figure 1 
The BK channel protein is a multimeric structure (homotetramer) composed of four identical 
pore-forming α subunits (BKα), encoded by a single gene (Slo1, KCNMA1). Each BKα has 
seven trans-membrane segments (S0-S6) and a large intracellular C-terminus region. The 
BKα protein shows three main structural domains, each with a distinct function. The voltage-
sensing domain (VSD) is located within the S1-S4 trans-membrane segments, able to sense 
membrane potential. The S5-S6 segments form the pore gate domain (PGD) including the 
activation gate, which controls K+ flux through the channel. The S6 segment serves as the 
major structural determinant for the channel gate. The primary voltage sensor is located on 
the S4 helix, which contains many positively charged residues, but only one of these 
participates in voltage sensing. The membrane-spanning domains VSD and PGD, interact 
through the S4-S5 linker and S6, and the hydrophobic segment (S0) leads to an extracellular 
NH2 terminus. The third domain is the cytosolic domain (CTD), which enables the channel to 
respond to changes in [Ca2+]i and other stimuli. The intracellular C-terminus has two tandem 
RCK (regulator of K
+ 
conductance) domains, RCK1 and RCK2, folded tightly against each 
other.  Channel sensitivity to Ca2+ is determined by a gating ring of eight RCK domains from 
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the four assembled α subunits; this gating ring is subjected to an expansion during channel 
gating. RCK2 domains have an aspartate-rich region that forms the ‘Ca2+ bowl’, showing a 
high Ca
2+ 
affinity. A low-affinity Ca
2+ 
recognition site has also been identified within the 
RCK1 domain, where another high-affinity Ca2+site is also present. RCK1 also mediates the 
channel’s sensitivity to Mg
2+
, Zn
2+
and Cd
2+
. The four β-subunits (β1-4) are encoded by a 
specific gene KCNMB1-4 (human) or kcnmb1-4 (mouse). These BK channel subunits have 
two transmembrane domains (STM1 and STM2) connected by a large loop on the 
extracellular side. β-subunits also show an intracellular N-terminus and C-terminus. Each β-
subunit is located between two adjacent α-subunits. γ subunits contain a single 
transmembrane domain, an N-terminal extracellular LRRD (leucine-rich repeat domain), and 
a short C-terminal tail.  
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